title: Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of diacerein, a drug with interleukin-1beta--inhibitory activity in vitro, in patients with knee osteoarthritis (OA).
  
  
  METHODS
  A total of 484 patients fulfilling the American College of Rheumatology criteria for knee OA were enrolled in this 16-week, randomized, double-blind, placebo-controlled, parallel study group with 3 diacerein dosages of 50 mg/day, 100 mg/day, and 150 mg/day (administered twice daily).
  
  
  RESULTS
  In the intent-to-treat population, 100 mg/day diacerein (50 mg twice daily) was significantly superior (P < 0.05) to placebo using the primary criterion (visual analog scale [VAS] assessment of pain on movement). Significant improvement (P < 0.05) was also observed for the secondary criteria, which included the Western Ontario and McMaster Universities OA Index (WOMAC), the WOMAC subscores, and the VAS assessment of handicap. In patients treated with diacerein dosages of 50 mg/day and 150 mg/day, favorable but not significant results were observed for the primary criterion. The best daily dosage of diacerein, calculated from the effect on the VAS assessment of pain on movement, was 90.1 mg. In the per-protocol population, the analysis of the primary criterion showed significant dose-dependent differences (P < 0.05) between each of the 3 diacerein dosages and the placebo. No differences were observed among the 3 diacerein groups. A significantly higher incidence (P < 0.05) of adverse events (AEs), as well as a higher rate of dropoout due to AEs, was observed in patients treated with 150 mg/day diacerein versus those treated with placebo, 50 mg/day diacerein, or 100 mg/day diacerein. Mild-to-moderate transient changes in bowel habits were the most frequent AEs, increasing with the dosage.
  
  
  CONCLUSIONS
  Diacerein, a drug for the treatment of OA, was shown to be an effective treatment for symptoms in patients with knee OA. Taking into account both efficacy and safety, the optimal daily dosage of diacerein for patients with knee OA is 100 mg/day (50 mg twice daily).
authors.affiliation: Centre hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Quebec, Canada.
authors.forename: J P
authors.initials: JP
authors.lastname: Pelletier
authors.forename: M
authors.initials: M
authors.lastname: Yaron
authors.forename: B
authors.initials: B
authors.lastname: Haraoui
authors.forename: P
authors.initials: P
authors.lastname: Cohen
authors.forename: M A
authors.initials: MA
authors.lastname: Nahir
authors.forename: D
authors.initials: D
authors.lastname: Choquette
authors.forename: I
authors.initials: I
authors.lastname: Wigler
authors.forename: I A
authors.initials: IA
authors.lastname: Rosner
authors.forename: A D
authors.initials: AD
authors.lastname: Beaulieu
mesh_terms: D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D015992:Body Mass Index; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D010919:Placebos; D013810:Therapeutic Equivalency
chemical_list: D000880:Anthraquinones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; C025292:diacerein